Radiomics, AI can guide NSCLC treatment decisions
Radiomics and artificial intelligence (AI) can be used to guide treatment of...Read more on AuntMinnie.comRelated Reading: Falling lung cancer rates drive cancer decline in U.S. Radiomics can aid management of lung cancer patients PET shows promise for detecting NSCLC recurrence New treatments lead to drop in lung cancer deaths Radiomics can predict treatment outcome for NSCLC (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 15, 2021 Category: Radiology Source Type: news

US Cancer Death Rates Drop for Second Year in a Row US Cancer Death Rates Drop for Second Year in a Row
Mortality from cancer continues to decline in the US, driven largely by major reductions in death rates from non-small cell lung cancer in men and women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 13, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer ’s 2020 World Conference on Lung Cancer
January 12, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral presentations, will be featured at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore taking place virtually January 28-31, 2021. The presentations include updated data from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations and two studies that characterize the high unmet need and lack of stand...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Statins May Give Boost to Mesothelioma Immunotherapy Drugs
This study, which included both patients with pleural mesothelioma and with advanced non-small cell lung cancer, found a potential synergy with the immunotherapy drugs. Opdivo and Keytruda, generically called nivolumab and pembrolizumab, respectively, are known as PD-1 inhibitors, drugs that restrict a protein from stopping immune response to cancer cells. “Statins may lead to prolonged antigen retention on cell membrane and strengthen antigen presentation to T cells, thus suggesting a potential synergy with PD-1 inhibitors,” the authors wrote. “The anti-tumor effect of statins might be attributed to an i...
Source: Asbestos and Mesothelioma News - January 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Roche ’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer
Basel, 5 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA), in combination with Tecentriq ® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression with no EGFR or ALK genomic tumour aberrations. Tiragolumab is the first anti-TIGIT molecule to be granted BTD from the FDA, and the designation is bas ed on randomised data from the phase II CITYS...
Source: Roche Media News - January 5, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer
Basel, 5 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA), in combination with Tecentriq ® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression with no EGFR or ALK genomic tumour aberrations. Tiragolumab is the first anti-TIGIT molecule to be granted BTD from the FDA, and the designation is bas ed on randomised data from the phase II CITYS...
Source: Roche Investor Update - January 5, 2021 Category: Pharmaceuticals Source Type: news

Cost effectiveness of nivolumab in advanced NSCLC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2021 Category: Drugs & Pharmacology Source Type: news

Exposure Limits in Lung Cancer Radiotherapy Help Curb Side Effects Exposure Limits in Lung Cancer Radiotherapy Help Curb Side Effects
In patients with non-small cell lung cancer, left anterior descending coronary-artery radiation exposure is associated with major adverse cardiac events and all-cause mortality, according to a new analysis.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 28, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Tagrisso Approved as Adjuvant Therapy for NSCLC With EGFR Mutations
TUESDAY, Dec. 22, 2020 -- Tagrisso (osimertinib) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, the U.S. Food and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 22, 2020 Category: Pharmaceuticals Source Type: news

Tagrisso Approved in the US for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer
21 December 2020 -- AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 21, 2020 Category: Drugs & Pharmacology Source Type: news

FDA OKs First Adjuvant Drug for Common Lung Cancer FDA OKs First Adjuvant Drug for Common Lung Cancer
Adjuvant osimertinib significantly cut the risk of disease recurrence or death in patients with stage IB-IIIA EGFR-mutated NSCLC in the ADAURA trial.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 21, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves First Adjuvant Therapy for Most Common Type of Lung Cancer
Today, the FDA approved the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations
On Dec. 18, 2020, FDA approved osimertinib (TAGRISSO, AstraZeneca Pharmaceuticals LP) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Drugs create balancing act for patients with non-small cell lung cancer
(Johns Hopkins Medicine) Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy researchers identified a correlation between multisystem immune-related adverse events and improved rates of survival. This new information will be helpful in discussing with patients the spectrum of immune side effects that may occur from immunotherapy and the implications for their future. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 14, 2020 Category: International Medicine & Public Health Source Type: news

Amgen's Sotorasib Granted Breakthrough Therapy Designation for Advanced or Metastatic Non-Small Cell Lung Cancer Patients with KRAS G12C Mutation
Sotorasib Also Accepted Into FDA's Real-Time Oncology Review Pilot Program New Drug Application Submission to FDA Planned by End of the Year THOUSAND OAKS, Calif., Dec. 8, 2020 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today ... Biopharmaceuticals, Oncology, FDA Amgen, Sotorasib, Non-Small Cell Lung Cancer, KRAS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 8, 2020 Category: Pharmaceuticals Source Type: news

What Is the Survival Rate of Non-Small Cell Lung Cancer?
Title: What Is the Survival Rate of Non-Small Cell Lung Cancer?Category: Diseases and ConditionsCreated: 12/8/2020 12:00:00 AMLast Editorial Review: 12/8/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - December 8, 2020 Category: Respiratory Medicine Source Type: news

Recent Trends in Adjuvant Chemotherapy Use in Elderly NSCLC Recent Trends in Adjuvant Chemotherapy Use in Elderly NSCLC
A new study examined recent trends in the patterns of use of adjuvant chemotherapy among elderly patients with lung cancer. What have we learned?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 4, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, N.J., December 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. The application marks the first-ever regulatory submission for the treatment of patients with NSCLC with EGFR exon 20 insertion mutations.[1] The Company...
Source: Johnson and Johnson - December 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, N.J., December 3, 2020 – The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 3, 2020 Category: Drugs & Pharmacology Source Type: news

Imfinzi Approved in the US for Less-Frequent, Fixed-Dose Use
20 November 2020 --  AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 20, 2020 Category: Drugs & Pharmacology Source Type: news

Lorlatinib Superior to Crizotinib for ALK - Positive NSCLC
Interim analysis shows risk for disease progression or death lower for first - line therapy with lorlatinib versus crizotinib (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 19, 2020 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

Lorlatinib Superior to Crizotinib for ALK-Positive NSCLC
THURSDAY, Nov. 19, 2020 -- Among patients with previously untreated advanced ALK-positive non-small cell lung cancer (NSCLC), progression-free survival is significantly longer for those who receive first-line therapy with lorlatinib versus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2020 Category: Pharmaceuticals Source Type: news

ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells
Targeted therapeutics for cancer generally exploit "oncogene addiction," a phenomenon in which the growth and survival of tumor cells depend on the activity of a particular protein. However, the efficacy of oncogene-targeted therapies varies substantially. For instance, targeting epidermal growth factor receptor (EGFR) signaling is effective in some non–small cell lung cancer (NSCLC) but not in triple-negative breast cancer (TNBC), although these cancers show a similar degree of increase in EGFR activity. Using a genome-wide CRISPR-Cas9 genetic knockout screen, we found that the Elongator (ELP) complex medi...
Source: Signal Transduction Knowledge Environment - November 17, 2020 Category: Science Authors: Cruz-Gordillo, P., Honeywell, M. E., Harper, N. W., Leete, T., Lee, M. J. Tags: STKE Research Articles Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for the cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with non-small cell lung cancer
Lung cancer causes more than 1.7 million deaths worldwide each year, with NSCLC accounting for about 85 percent of all cases[1] The cobas EGFR Mutation Test v2 is FDA approved as a companion diagnostic for the detection of EGFR mutations in NSCLC for bo... Diagnostics, Oncology, FDA Roche Group, cobas, EGFR Mutation Test, NSCLC, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 29, 2020 Category: Pharmaceuticals Source Type: news

Validation of ERCC1/2 signature as radiosensitivity biomarker for tumor & normal tissues in NSCLC
(NRG Oncology) A genetic analysis of non-small cell lung cancer (NSCLC) patients on the phase III NRG Oncology RTOG 0617 clinical trial assessing radiation dose discovered that high dose radiation therapy is associated with shorter survival times among patients with a radiation-sensitive genotype in DNA repair pathway. These findings were presented at the virtual edition of the American Society for Radiation Oncology's (ASTRO) Annual Meeting in October 2020. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 28, 2020 Category: Cancer & Oncology Source Type: news

Dracen Pharmaceutical ’s DRP-104 Granted U.S. FDA Fast Track...
Dracen to work closely with FDA to advance the clinical program for the treatment of NSCLC with specific mutations(PRWeb October 27, 2020)Read the full story at https://www.prweb.com/releases/dracen_pharmaceuticals_drp_104_granted_u_s_fda_fast_track_designation_for_the_treatment_of_non_small_cell_lung_cancer/prweb17497203.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 27, 2020 Category: Pharmaceuticals Source Type: news

Radiomics can aid management of lung cancer patients
Researchers from the H. Lee Moffitt Cancer Center and Research Institute in...Read more on AuntMinnie.comRelated Reading: PET shows promise for detecting NSCLC recurrence New treatments lead to drop in lung cancer deaths Radiomics can predict treatment outcome for NSCLC Can radiomics improve CT lung cancer screening? AI improves interpretation of CT lung cancer images (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 26, 2020 Category: Radiology Source Type: news

Inhibitor of KRAS gene mutation shows promise in lung, bowel and other solid tumors
(European Organisation for Research and Treatment of Cancer) New results from a clinical trial of a drug that targets a cancer-causing mutation in the KRAS gene have shown that it can shrink tumours and is well-tolerated by patients. In two presentations to the 32nd EORTC-NCI-AACR cancer symposium, researchers involved in the KRYSTAL-1 phase I/II clinical trial said that adagrasib (MRTX849) showed clinical activity and manageable adverse side effects in patients with non-small cell lung cancer, colorectal cancer and other solid tumours. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 25, 2020 Category: International Medicine & Public Health Source Type: news

Moffitt researchers develop tool to better predict treatment course for lung cancer
(H. Lee Moffitt Cancer Center& Research Institute) In a new article published inNature Communications, Moffitt Cancer Center researchers demonstrate how a deep learning model using positron emission tomography/computerized tomography radiomics can identify which non-small cell lung cancer patients may be sensitive to tyrosine kinase inhibitor treatment and those who would benefit from immune checkpoint inhibitor therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 16, 2020 Category: International Medicine & Public Health Source Type: news

FDA Approves Opdivo, Yervoy Combination for Mesothelioma
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - October 5, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA Approves Opdivo, Yervoy Combination for Mesothelioma
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - October 5, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Prognostic Biomarkers in NSCLC Treated With Immunotherapy Prognostic Biomarkers in NSCLC Treated With Immunotherapy
What can these potential biomarkers tell us about the prognosis of immunotherapy-treated non-small cell lung cancer?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 5, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Liquid biopsies timely and effective testing method for NSCLC patients in Canada
(International Association for the Study of Lung Cancer) Next-generation sequencing (NGS) of cell-free DNA (cfDNA) obtained from blood samples may improve diagnostic testing in patients with advanced NSCLC, and may also be faster and less expensive compared to standard tissue profiling, according to research presented today at the IASLC 2020 Lung Cancer Hot Topic: Liquid Biopsy Virtual Conference. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 2, 2020 Category: Cancer & Oncology Source Type: news

Immunotherapy Drug Helping Lung Cancer Patients
The immunotherapy drug Tecentriq (atezolizumab) was approved earlier this year by the U.S. Food and Drug Administration to treat patients with newly diagnosed non-small cell lung cancers (NSCLC), which comprise up to 85% of all lung tumors. (Source: WebMD Health)
Source: WebMD Health - October 1, 2020 Category: Consumer Health News Source Type: news

Atezolizumab Prolongs Survival in NSCLC With PD - L1 Expression
Overall survival longer than for chemotherapy in metastatic NSCLC with high PD - L1 expression (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 1, 2020 Category: Respiratory Medicine Tags: Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

Atezolizumab Prolongs Survival in NSCLC With PD-L1 Expression
THURSDAY, Oct. 1, 2020 -- For patients with non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression, treatment with atezolizumab results in longer overall survival than chemotherapy, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 1, 2020 Category: Pharmaceuticals Source Type: news

Monthly News Roundup - September 2020
Genentech’s Gavreto Cleared for RET Fusion-Positive NSCLC Gavreto (pralsetinib) is a RET kinase inhibitor used for the treatment of adults with metastatic rearranged during transfection (RET) fusion positive non-small cell lung cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 30, 2020 Category: Pharmaceuticals Source Type: news

Clinical trial of selpercatinib shows strong response for patients with non-small cell lung cancer
(SingHealth) Drug shown to precisely target non-small cell lung cancer driven bymutations to gene RET. Majority of patients on trial experience shrinking tumours and live formore than a year without disease progression. National Cancer Centre Singapore, one of a handful of three Asian centres to participate in the trial, has implemented routine testing of the gene RET for all lung cancer patients. Findings published in high impact factor journal, New England Journal of Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 28, 2020 Category: International Medicine & Public Health Source Type: news

Researchers offer a guide to optimum PET lung imaging
Can you name the best strategies to optimize FDG-PET/CT to assess lung disease?...Read more on AuntMinnie.comRelated Reading: PET shows promise for detecting NSCLC recurrence PET agent shows promise for imaging lung inflammation What causes PTE in COVID-19 patients? SNMMI: Multicancer radiotracer wins Image of the Year Novel PET tracer may improve NSCLC patient management (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 25, 2020 Category: Radiology Source Type: news

Lorlatinib: Another First-Line Option for ALK-Positive NSCLC? Lorlatinib: Another First-Line Option for ALK-Positive NSCLC?
First-line lorlatinib significantly prolonged progression-free survival compared with crizotinib in advanced ALK-positive nonsmall cell lung cancer, according to a phase 3 interim analysis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

What Your Blood Tells You About Cancer
Blood tests can tell us a lot about what’s going on in our bodies—from whether we’re eating too much sugar to whether we’re harboring any infectious diseases. Scientists lately have been working on ways to use similar diagnostic tools for cancer, which have the potential to dramatically increase the amount of information doctors use to figure out the best treatments for their patients. Called liquid biopsies, these tests are designed to pick up genetic material shed by cancer tumors into the blood, which lets doctors avoid the invasive procedures needed to extract samples directly from tumors. That ...
Source: TIME: Health - September 22, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Source Type: news

Sotorasib Is a'Triumph of Drug Discovery' in Cancer Sotorasib Is a'Triumph of Drug Discovery' in Cancer
The drug inhibits KRAS p.G12C-mutant tumors, which are seen in about 13% of patients with non-small cell lung cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 21, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

No benefit for post-operative radiotherapy in non-small-cell lung cancer
(European Society for Medical Oncology) Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant chemotherapy shows no statistically significant difference in 3-year disease-free survival (DFS), according to data presented at ESMO 2020. These results give the oncology community a long-awaited answer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 20, 2020 Category: International Medicine & Public Health Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

GAVRETO (pralsetinib), FDA Approved for Treatment of Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., Sept. 17, 2020 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Blueprint Medicines as a specialty pharmacy provider for GAVRETOTM (pralsetinib) for the treatment of adult patients with metastatic RET fusion-p... (Source: McKesson News)
Source: McKesson News - September 17, 2020 Category: Information Technology Source Type: news

PET shows promise for detecting NSCLC recurrence
F-18 FDG PET/CT shows promise for detecting recurrence of disease in non-small...Read more on AuntMinnie.comRelated Reading: PET radiomics tailor head/neck cancer treatment Nuclear medicine volume plummets due to COVID-19 Dual-phase technique improves PET/CT brain tumor imaging PET/CT could be useful for diagnosing fever PET/MRI ups lesion detection by 15% for some cancers (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 17, 2020 Category: Radiology Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news